<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04703842</url>
  </required_header>
  <id_info>
    <org_study_id>SRD-001-1001</org_study_id>
    <nct_id>NCT04703842</nct_id>
  </id_info>
  <brief_title>Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease</brief_title>
  <acronym>CUPID-3</acronym>
  <official_title>A Phase 1/2 Trial of the Safety and Efficacy of SRD-001 (AAV1/SERCA2a) in Subjects With Heart Failure With Reduced Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sardocor Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sardocor Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is believed that targeted SERCA2a enzyme replacement in HFrEF patients will correct&#xD;
      defective intracellular Ca2+ hemostasis, resulting in improved cardiac contractile function&#xD;
      and energetics which will, in turn, translate to improved clinical outcomes. Additionally, it&#xD;
      is hypothesized that correcting SERCA2a dysfunction will also improve coronary blood flow&#xD;
      through correction of the impaired endothelium-dependent nitric oxide-mediated vasodilatation&#xD;
      observed in heart failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CUPID-3 Trial is an interventional study of SRD-001, an adeno-associated virus serotype 1&#xD;
      (AAV1) vector expressing the transgene for sarco(endo)plasmic reticulum Ca2+ ATPase 2a&#xD;
      isoform (SERCA2a), in anti-AAV1 neutralizing antibody (NAb) negative subjects with ischemic&#xD;
      or non-ischemic cardiomyopathy and New York Heart Association (NYHA) class III/IV symptoms of&#xD;
      heart failure with reduced ejection fraction (HFrEF).&#xD;
&#xD;
      The Phase 1 trial is an open-label, uncontrolled study investigating one dose of SRD-001 at&#xD;
      3E13 viral genomes (vg) in 3 to 6 subjects.&#xD;
&#xD;
      The Phase 2 is a randomized, double-blind, placebo-controlled trial with prospective&#xD;
      assignment to a single dose of either SRD-001 at 3E13 vg or placebo in a 1:1 ratio and a&#xD;
      total sample size of N=50.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in symptomatic parameters</measure>
    <time_frame>Baseline to Month 6 and Month 12</time_frame>
    <description>New York Heart Association classification (I, II, III or IV)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in symptomatic parameters</measure>
    <time_frame>Baseline to Month 6 and Month 12</time_frame>
    <description>Quality of life as assessed by Kansas City Cardiomyopathy Questionnaire: 0-24, very poor to poor; 25-49, poor to fair; 50-74, fair to good; and 75-100, good to excellent</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in physical parameter</measure>
    <time_frame>Baseline to Month 6 and Month 12</time_frame>
    <description>Distance walked during the 6MWT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in LV function/remodeling</measure>
    <time_frame>Baseline to Month 6 and Month 12</time_frame>
    <description>Left ventricular end systolic volume (LVESV) as assessed by echocardiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of recurrent events</measure>
    <time_frame>Baseline to Month 6 and Month 12</time_frame>
    <description>HF-related hospitalization, ambulatory worsening heart failure, all-cause death, MCSD and transplant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of adverse events</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Treatment-emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who complete the trial</measure>
    <time_frame>12 months</time_frame>
    <description>Those who complete the trial vs withdraw consent, are lost to follow-up, or withdrawn due to an AE or other reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant medication use</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Changes in heart failure related medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormal laboratory test results</measure>
    <time_frame>Baseline to Month 6 and Month 12</time_frame>
    <description>Hematologic, serum chemistries, NT-proBNP and troponin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormal ECG results</measure>
    <time_frame>Baseline to Month 6 and Month 12</time_frame>
    <description>New arrhythmias</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormal physical examination findings</measure>
    <time_frame>Baseline to Month 6 and Month 12</time_frame>
    <description>Change from baseline in physical examination findings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormal findings from interrogation of implantable cardioverter defibrillator</measure>
    <time_frame>Baseline to Month 6 and Month 12</time_frame>
    <description>New arrhythmias</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Congestive Heart Failure</condition>
  <condition>Heart Failure, Systolic</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>SRD-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3E13 vg; one-time intracoronary infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One-time intracoronary infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SRD-001</intervention_name>
    <description>AAV1/SERCA2a</description>
    <arm_group_label>SRD-001</arm_group_label>
    <other_name>MYDICAR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>SRD-001 matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Chronic ischemic or non-ischemic cardiomyopathy&#xD;
&#xD;
          -  NYHA class III/IV&#xD;
&#xD;
          -  LVEF ≤35%&#xD;
&#xD;
          -  Maximal, optimized heart failure therapy; ICD&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Restrictive cardiomyopathy, hypertrophic cardiomyopathy, acute myocarditis,&#xD;
             pericardial disease, amyloidosis, infiltrative cardiomyopathy, uncorrected thyroid&#xD;
             disease or discrete left ventricular (LV) aneurysm&#xD;
&#xD;
          -  Prior heart transplantation, left ventricular reduction surgery (LVRS),&#xD;
             cardiomyoplasty, passive restraint device (e.g., CorCap™ Cardiac Support Device),&#xD;
             mechanical circulatory support device (MCSD) or cardiac shunt&#xD;
&#xD;
          -  Likely to receive cardiac resynchronization therapy, cardiomyoplasty, LVRS,&#xD;
             conventional revascularization procedure or valvular repair in the 6 months following&#xD;
             treatment&#xD;
&#xD;
          -  Likely need for an immediate heart transplant or MCSD implant due to hemodynamic&#xD;
             instability&#xD;
&#xD;
          -  Inadequate hepatic and renal function&#xD;
&#xD;
          -  Diagnosis of, or treatment for, any cancer within the last 5 years except for basal&#xD;
             cell carcinoma or carcinomas in situ where surgical excision was considered curative&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jeff Rudy</last_name>
    <phone>858-752-2941</phone>
    <email>Jeff.Rudy@sardocorcorp.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

